Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...
New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...
The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...
After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...
The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster ...
The French pharma’s venture arm will use the funds to back companies working in immunology, neurology, rare diseases and vaccines.
The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do ...
The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price ...
The clearance of Keytruda QLEX follows similar approvals for Bristol Myers and Roche. Elsewhere, MBX’s parathyroidism drug ...
After an earlier rejection that drew criticism from some observers, the FDA quickly accepted Stealth BioTherapeutics’ new ...
The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.
The denial sets back a drug Scholar Rock hopes to become part of a new standard of care for spinal muscular atrophy, treatment for which has changed dramatically over the last decade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback